| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | September 7, 2023 |
| Accession Number: | 0001193125-23-227368 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | September 7, 2023 |
| Accession Number: | 0001193125-23-227368 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/10/2023 | $57.72 | Overweight → Equal Weight | Wells Fargo |
| 2/10/2023 | $63.00 → $52.00 | Buy → Neutral | Citigroup |
| 2/10/2023 | $51.00 → $52.50 | Buy → Hold | Truist |
| 1/6/2023 | Buy → Hold | Needham | |
| 10/18/2022 | $53.00 | Overweight | Barclays |
| 10/12/2022 | $45.00 | Hold | Jefferies |
| 4/13/2022 | $60.00 → $65.00 | Buy | Truist |
| 3/28/2022 | $58.00 | Overweight | Wells Fargo |
15-12G - NUVASIVE INC (0001142596) (Filer)
EFFECT - NUVASIVE INC (0001142596) (Filer)
EFFECT - NUVASIVE INC (0001142596) (Filer)
SC 13G/A - NUVASIVE INC (0001142596) (Subject)
SC 13G - NUVASIVE INC (0001142596) (Subject)
SC 13G/A - NUVASIVE INC (0001142596) (Subject)
Wells Fargo downgraded NuVasive from Overweight to Equal Weight and set a new price target of $57.72
Citigroup downgraded NuVasive from Buy to Neutral and set a new price target of $52.00 from $63.00 previously
Truist downgraded NuVasive from Buy to Hold and set a new price target of $52.50 from $51.00 previously
–U.S. Cervical continues to deliver greater than 20% year-over-year growth––International net sales grew 6.8% as reported and 9.8% on a constant currency basis– SAN DIEGO, Aug. 2, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2023. Second Quarter 2023 Highlights Net sales were $317.8 million, a 2.4% increase as reported and a 3.1% increase on a constant currency basi
SAN DIEGO, July 24, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that it will release its second quarter 2023 results on Wednesday, August 2, 2023, after the close of the market. NuVasive will hold a conference call on Wednesday, August 2, 2023, at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results of its financial performance for the second quarter of 2023. The dial-in numbers are 1-877-407-9039 for domestic calle
–Continued above-market worldwide net sales growth of 5.8% as reported and 7.7% on a constant currency basis––U.S. cervical delivers sixth consecutive quarter of greater than 20% growth, driven by C360 and the Simplify Cervical Disc– SAN DIEGO, May 10, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended March 31, 2023. First Quarter 2023 Highlights Net sales were $307.7 million, a
4 - NUVASIVE INC (0001142596) (Issuer)
4 - NUVASIVE INC (0001142596) (Issuer)
4 - NUVASIVE INC (0001142596) (Issuer)
Morgan Stanley analyst Jonathan Demchick maintains NuVasive (NASDAQ:NUVA) with a Equal-Weight and raises the price target from $40 to $45.
Over the past 3 months, 7 analysts have published their opinion on NuVasive (NASDAQ:NUVA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 4 3 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 1 0 0 2M Ago 0 0 0 0 0 3M Ago 0 3 2 0 0 In the last 3 months, 7 analysts have offered 12-month price targets for NuVasive. The company has an average price target of $52.0 with a high of $58.00 and a low of $40.00. Below is a summary of how these 7 analysts rated NuVasive over the past 3 mon
Barclays analyst Matt Miksic maintains NuVasive (NASDAQ:NUVA) with a Overweight and raises the price target from $56 to $58.
SAN DIEGO, Aug. 30, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will continue its partnership with the Scoliosis Research Society (SRS) as a double diamond sponsor and will attend the 58th Annual Meeting held September 6-9, 2023, in Seattle. "We partner with esteemed societies like SRS because of our shared dedication to clinical research, education, and thought leadership around advancing patient care, especi
NEW YORK, Aug. 28, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Friday, September 1: Goosehead Insurance Inc. (NASD: GSHD) will replace NuVasive Inc. (NASD: NUVA) in the S&P SmallCap 600. S&P MidCap 400 constituent Globus Medical Inc. (NYSE:GMED) is acquiring NuVasive in a deal expected to close soon pending final conditions.Jackson Financial Inc. (NYSE:JXN) will replace NexTier Oilfield Solutions Inc. (NYSE:NEX) in the S&P SmallCap 600. S&P SmallCap 600 constituent Patterson-UTI Energy Inc. (NASD: PTEN) is acquiring NexTier Oilfield Solutions in a deal expected to close soon pending final cond
–U.S. Cervical continues to deliver greater than 20% year-over-year growth––International net sales grew 6.8% as reported and 9.8% on a constant currency basis– SAN DIEGO, Aug. 2, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2023. Second Quarter 2023 Highlights Net sales were $317.8 million, a 2.4% increase as reported and a 3.1% increase on a constant currency basi
SAN JOSE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today the appointment of Tamara Elias, M.D., Senior Vice President at Nuance, and Scott Huennekens, executive chairperson at Hyperfine, Wondr Medical, Acutus Medical and Envista Holdings Corporation, to the BrightInsight Advisory Council. Dr. Elias and Huennekens bring deep and complimentary experience to this group of industry experts, who work with BrightInsight leadership to advance the company's vision to transform patient outcomes globally through the power of digital technology. Dr. Elias and Huennek
The new board member will provide extensive expertise to expand the TempTraq® remote patient monitoring platform Blue Spark Technologies Inc., a leader in wearable remote patient monitoring solutions, announced today the appointment of John DeFord, Ph.D. to its board of directors. Dr. DeFord's appointment, effective April 13th, 2022, brings the number of board members to five. "This is really an inflection point for the company and it's an exciting time to be involved. I look forward to helping mold the future of their technology," said Dr. DeFord. "I'm particularly excited to see the technology come together that will make an impact in patient's lives." "We are proud to welcome John to
SAN DIEGO, Jan. 31, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the appointment of Andrew (Drew) C. Morton as senior vice president and chief human resources officer (CHRO) effective February 7, 2022. Mr. Morton brings more than 25 years of experience in human resources, talent development, employee experience, and diversity and inclusion. As CHRO, Mr. Morton will oversee all human resources aspects of the Company